2023年欧洲内科肿瘤学(ESMO)大会定于欧洲中部夏令时间(CET)在西班牙马德里举行。日前,ESMO官方已公布除Late-breaking abstracts(LBAs)外的所有口头摘要题目及作者信息。
【肿瘤资讯】特将简短口头报告专场(Mini Oral Session)、论文优选专场(Proffered Paper Session)的黑色素瘤研究摘要信息整理如下,与您同鉴!
简短口头报告专场(Mini Oral Session)
摘要号:1022MO
题目:Predicting overall survival of patients with melanoma and NSCLC treated with immunotherapy using AI combining total tumor volume and tumor heterogeneity on CT-Scans.
使用AI结合CT扫描上的总肿瘤体积和肿瘤异质性预测用免疫疗法治疗的黑色素瘤和非小细胞肺癌患者的总生存期
讲者:L. Dawi(Bourg-la-reine, France)
摘要号:1084MO
题目:Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial
纳武利尤单抗联合伊匹木单抗治疗无症状脑转移的黑色素瘤患者:多中心III期NIBIT-M2研究7年生活质量的结局
讲者:A. Di Giacomo(Siena, Italy)
摘要号:1085MO
题目:ATezolizumab, bevAcizumab, and Cobimetinib (TACo) in patients (pts) with PD1 refractory melanoma brain metastases (MBM)
阿替利珠单抗、贝伐珠单抗和考比替尼(TACo)治疗PD1难治性黑色素瘤脑转移(MBM)患者(pts)
讲者:E. Burton(Houston, US)
摘要号:1086MO
题目:Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase 2 C-144-01 study
Lifileucel肿瘤浸润淋巴细胞(TIL)细胞治疗在免疫检查点抑制剂(ICI)治疗进展后的晚期粘膜黑色素瘤患者(pts):II期C-144-01研究的结果
讲者:G.-U. Grigoleit(Duisburg, Germany)
摘要号:1024MO
题目:Interpretable AI-identified spatial tumor microenvironment (TME) neighborhoods associate with severe immune-related adverse events (irAE) and progressive disease (PD) in patients with melanoma treated with anti-PD-1- based therapy
可解释AI识别的空间肿瘤微环境(TME)邻域与接受基于抗PD-1治疗的黑色素瘤患者的严重免疫相关不良事件(irAE)和疾病进展(PD)相关
讲者:D. Jimenez-Sanchez(Baltimore, US)
论文优选专场
摘要号:1081O
题目:ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (Daro + Crizo) combination in metastatic uveal melanoma (MUM)
darovasertib+克唑替尼(Daro + Crizo)联合治疗转移性葡萄膜黑色素瘤(MUM)的ctDNA减少和临床疗效
讲者:M. Mckean(Nashville, US)
摘要号:1082O
题目:Concurrent Intrathecal (IT) and Intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) with leptomeningeal disease (LMD)
同时鞘内(IT)和静脉内(IV)纳武单抗(N)治疗患有软脑膜疾病(LMD)的黑色素瘤(MM)患者(pts)
讲者:I. Glitza(Houston, US)
摘要号:1017O
题目:NTC-001: A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen-specific T cell product, in patients with advanced or metastatic melanoma
NTC-001:一项在晚期或转移性黑色素瘤患者中测试BNT 221(一种非工程化新抗原特异性T细胞产品)的安全性和有效性的I期研究
讲者:J. Borgers(Amsterdam, Netherlands)
(本文依照报告日期和出场排序整理,如有错误或遗漏,敬请留言指正。)
https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/session/calendar
排版编辑:肿瘤资讯-Kate